Association of dynamic changes in serum levels of HBV DNA and risk of hepatocellular carcinoma
Association of dynamic changes in serum levels of HBV DNA and risk of hepatocellular carcinoma
复制标题
DOI：
10.1007/s44194-022-00008-9
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Xiangjun Zhai
中科院分区：
文献类型：
--
作者：
Xin Xu;Jie Jiang;Ci Song;Chengxiao Yu;Liguo Zhu;Jiao Qian;Ting Tian;Yuqing Ding;Fengcai Zhu;Zhibin Hu;Xiangjun Zhai
Abstract Background and aims We aimed to examine the risk of HCC associated with the long-term change patterns in HBV DNA levels. Methods We conducted a longitudinal study of 6,301 participants with chronic HBV infection (CHB) from October 2012 to June 2019 and measured serum levels of HBV DNA at enrollment and during follow-up. The dynamic change patterns of HBV DNA were identified by group-based trajectory models. The associations between change patterns of HBV DNA and HCC were estimated using Cox regression models. Results During 35,112 person-years of follow-up, 182 participants developed HCC (518.34 per 10 5 person-years). Five trajectory groups of repeated measurement of HBV DNA were identified. The risk of HCC was significantly higher for the “high, fast-declined” group whose HBV DNA spontaneously decreased from > 2000 IU/mL at baseline compared with those with persistent undetected HBV DNA (reference group; 963.96 per 10 5 person-years, HR = 2.62, 95% CI, 1.82 to 3.77, P 20,000 IU/mL from baseline to the end of follow-up also showed an obviously higher cumulative HCC incidence rate (1193.29 per 10 5 person-years, HR = 4.17, 95% CI, 1.87 to 9.31, P < 0.001). The positive association remained stable after taking the potential effect of time-dependent antiviral treatment into account. Conclusions Significant variability in serum levels of HBV DNA presented during long-term follow-up. Regular monitoring of serum levels of HBV DNA and antiviral treatment are required for the clinical management of CHB patients, as well as those with undetected HBV DNA.
